Sakurai Nobuko, Kozuka Mutsuo, Tokuda Harukuni, Nobukuni Yoshitaka, Takayasu Junko, Nishino Hoyoku, Kusano Akiko, Kusano Genjiro, Nagai Masahiro, Sakurai Yojiro, Lee Kuo Hsiung
Natural Products Laboratory, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA.
Bioorg Med Chem. 2003 Mar 20;11(6):1137-40. doi: 10.1016/s0968-0896(02)00432-7.
Cimigenol (1) and 39 related compounds were screened as potential antitumor promoters by examining the ability of the compounds to inhibit Epstein-Barr virus early antigen (EBV-EA) activation (induced by 12-O-tetradecanoylphorbol-13-acetate) in Raji cells. Structure-activity relationship analysis indicated that compound 1 showed the highest activity and also exhibited significant inhibitory effects on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test. These data suggest that 1 and the related compounds might be valuable anti-tumor promoters.
